• eoh2014

  • Slideshow_knowmorehepc

  • Slideshow_hivhealthreform

  • slide_communityconnext

  • Slideshow_prep

Medicare will cover a one-time, no-cost hepatitis C test for beneficiaries born 1945–1965


Reprinted from NVHR. On June 2, 2014, the Centers for Medicare & Medicaid Services (CMS) announced that Medicare will cover hepatitis C testing at no cost to beneficiaries whom the U.S. Preventive Services Task Force recommends be screened. Specifically, Medicare will cover a one-time test for…Read More

California pharmacists may sell syringes to adults without a prescription to help prevent HIV and hepatitis C


VIEW PDF. Pharmacists across California may sell or furnish any number of syringes to adults 18 and older without a prescription, as of January 1, 2015, as part of the state’s strategy to prevent the spread of HIV, hepatitis C, and other blood-borne pathogens. Assembly Bill…Read More

“Hepatitis C in Corrections”, in Positively Aware


In the September/October issue of Positively Aware magazine, Project Inform’s Andrew Reynolds reports on the current state of the hepatitis C epidemic in the US prison system. “Social policy decisions can have far-reaching effects and unintended consequences. Rrther than taking a public health approach to address…Read More

New hepatitis C drug Harvoni receives FDA approval


Also read the FDA press release here. On Friday, October 10, 2014, the FDA approved Harvoni (ledipasvir/sofosbuvir) for the treatment of hepatitis C (HCV) genotype 1 (GT1). This treatment marks a significant breakthrough in the treatment of HCV: It is the first once daily, single tablet…Read More

ED drugs tied to sexual risk and STIs in HIV-positive men

IDWeek 2014, October 8-12, 2014, Philadelphia, Mark Mascolini, NATAP.org Greater sexual risk taking, substance abuse, and a history of sexually transmitted infection (STI) proved more likely in 1170 HIV-positive men prescribed erectile dysfunction drugs (EDD) at the University of Alabama at Birmingham (UAB) HIV clinic [1]….Read More

Casualties of the PrEP wars?


As POZ’s crack health writer, Ben Ryan, explains in the magazine’s most recent issue, PrEP works if you take it. Fortunately, we seem to be moving on from that debate and what’s left to figure out is whether it will ignite or extinguish the epidemic in…Read More

FDA approves two new doses of elvitegravir, in addition to its current use in Stribild


On September 24, 2014, the FDA approved two new standalone doses of the integrase inhibitor elvitegravir, which now comes with the brand name Vitekta. The 85mg dose can be taken with Reyataz (atazanavir) and Kaletra (lopinavir), while the 150mg dose can be taken with Prezista (darunavir),…Read More